MediciNova Stock Forecast, Price & News

MediciNova (NASDAQ:MNOV) Frequently Asked Questions

Is MediciNova a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MediciNova stock.
View analyst ratings for MediciNova or view top-rated stocks.

How has MediciNova's stock been impacted by COVID-19?

MediciNova's stock was trading at $3.29 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MNOV stock has decreased by 1.8% and is now trading at $3.23.
View which stocks have been most impacted by COVID-19.

When is MediciNova's next earnings date?

MediciNova is scheduled to release its next quarterly earnings announcement on Thursday, February 17th 2022.
View our earnings forecast for MediciNova.

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) announced its quarterly earnings results on Monday, October, 26th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.12) by $0.04.
View MediciNova's earnings history.

What price target have analysts set for MNOV?

2 equities research analysts have issued twelve-month price targets for MediciNova's shares. Their forecasts range from $15.00 to $15.00. On average, they expect MediciNova's share price to reach $15.00 in the next year. This suggests a possible upside of 364.4% from the stock's current price.
View analysts' price targets for MediciNova or view top-rated stocks among Wall Street analysts.

Who are MediciNova's key executives?

MediciNova's management team includes the following people:

• Yuichi Iwaki, President, Chief Executive Officer & Director
• Douglas Paulin, Chief Financial Officer
• Federico Gaetani, Chief Scientific Officer
• Kazuko Matsuda, Director & Chief Medical Officer
• Geoffrey G. O'Brien, Vice President & Executive Officer

Who are some of MediciNova's key competitors?

Some companies that are related to MediciNova include Annexon (ANNX), Eagle Pharmaceuticals (EGRX), Amryt Pharma (AMYT), Collegium Pharmaceutical (COLL), Fulcrum Therapeutics (FULC), OrganiGram (OGI), DiaMedica Therapeutics (DMCAF), SIGA Technologies (SIGA), Veru (VERU), ORIC Pharmaceuticals (ORIC), BioXcel Therapeutics (BTAI), Phathom Pharmaceuticals (PHAT), Immuneering (IMRX), G1 Therapeutics (GTHX) and Inventiva (IVA).
View all of MNOV's competitors.

What other stocks do shareholders of MediciNova own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MediciNova investors own include Dynavax Technologies (DVAX), VBI Vaccines (VBIV), OPKO Health (OPK), Iovance Biotherapeutics (IOVA), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Trevena (TRVN), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX) and CymaBay Therapeutics (CBAY).

What is MediciNova's stock symbol?

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

Who are MediciNova's major shareholders?

MediciNova's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.34%), Geode Capital Management LLC (0.89%), Millennium Management LLC (0.78%), Marshall Wace LLP (0.58%), Barclays PLC (0.31%) and Renaissance Technologies LLC (0.26%). Company insiders that own MediciNova stock include Hideki Nagao, Kazuko Matsuda and Yuichi Iwaki.
View institutional ownership trends for MediciNova.

Which major investors are selling MediciNova stock?

MNOV stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Marshall Wace LLP, Goldman Sachs Group Inc., Morgan Stanley, and Renaissance Technologies LLC.
View insider buying and selling activity for MediciNova or view top insider-selling stocks.

Which major investors are buying MediciNova stock?

MNOV stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Barclays PLC, Dimensional Fund Advisors LP, BlackRock Inc., and UBS Group AG. Company insiders that have bought MediciNova stock in the last two years include Kazuko Matsuda, and Yuichi Iwaki.
View insider buying and selling activity for MediciNova or or view top insider-buying stocks.

How do I buy shares of MediciNova?

Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MediciNova's stock price today?

One share of MNOV stock can currently be purchased for approximately $3.23.

How much money does MediciNova make?

MediciNova has a market capitalization of $158.41 million. The biopharmaceutical company earns $-13.85 million in net income (profit) each year or ($0.23) on an earnings per share basis.

How many employees does MediciNova have?

MediciNova employs 9 workers across the globe.

When was MediciNova founded?

MediciNova was founded in 2000.

What is MediciNova's official website?

The official website for MediciNova is medicinova.com.

Where are MediciNova's headquarters?

MediciNova is headquartered at 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037.

How can I contact MediciNova?

MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at (858) 373-1500, via email at [email protected], or via fax at 858-404-0048.